Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...
Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company’s common stock, payable September 1, 2026, to holders of the Common Stock of record at the close of business on July 24, 2026.
Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (MBC) following induction treatment. The approval is based on positive results from the Alliance Foundation Trials, LLC (AFT)-sponsored Phase 3 PATINA trial.
